

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

HEALTH TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Guidance development

STA Avelumab with axitinib for untreated advanced renal cell carcinoma (MA review of TA645)

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

Final draft guidance

(when no draft guidance was issued)

- | |
|--|
| 1. Have the potential equality issues identified during the scoping process been addressed by the committee, and, if so, how? |
| During scope consultation it was noted that the scope should address equity of access to avelumab with axitinib on the NHS regardless of where the person lives, for people with all subtypes of advanced renal cell carcinoma (RCC), including RCC with sarcomatoid and rhabdoid features, and RCC brain metastases. The committee did not identify any equalities issues. |
| 2. Have any other potential equality issues been raised in the submissions, expert statements or academic report, and, if so, how has the committee addressed these? |
| <p>The company noted that it was important to consider equity of access to treatments across International Metastatic RCC Database Consortium risk groups. Presently, no immunotherapy containing regimens are routinely recommended by NICE for first-line treatment in favourable risk group, only in intermediate-/poor-risk group.</p> <p>Within statements and during the committee meeting the clinical and patient experts noted the unmet need in first line RCC and favourable risk group. Avelumab with axitinib will be the only immunotherapy available for the favourable risk group.</p> |

Technology appraisals: Guidance development

Equality impact assessment for the single technology appraisal of avelumab with axitinib for untreated advanced renal cell carcinoma (MA review of TA645)

Committee have recommended avelumab with axitinib for the favourable risk group.

3. Have any other potential equality issues been identified by the committee, and, if so, how has the committee addressed these?

NA

4. Do the recommendations make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?

NA - avelumab with axitinib is recommended for the favourable risk group that had fewer treatment options compared with intermediate-/poor-risk group

5. Is there potential for the recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

NA

6. Are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 4 or 5, or otherwise fulfil NICE's obligations to promote equality?

NA

7. Have the committee's considerations of equality issues been described in the final draft guidance, and, if so, where?
The committee did not identify any equalities issues.

Approved by Associate Director (name): Ross Dent

Date: 06/11/2025